Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellceutix, a bio-pharmaceutical company, has concluded an agreement with Formatech, to formulate Kevetrin for a Phase 1 study. Kevetrin will be presented as a lyophilized powder for reconstitution in saline solution at the time of use.
Subscribe to our email newsletter
Cellceutix said that Kevetrin is being developed to treat drug resistant cancers. The company has recently reported that Kevetrin showed greater tumor shrinkage than standard therapies in animal models of resistant lung cancer, breast and colon cancer cell lines.
George Evans, CEO of Cellceutix, said: “This agreement allows us to stay on track for our IND filing. Formatech is a quality formulator and has been very flexible and responsive in meeting our needs.”
Indu Isaacs, CEO of Formatech, said: “We are very pleased to have been selected by Cellceutix to participate in this exciting research effort. We look forward to helping Cellceutix achieve its goal of reaching Phase 1 with Kevetrin as soon as possible.”